Takayanagi, Shin-ichiro http://orcid.org/0000-0002-5158-1920
Chuganji, Sayaka
Tanaka, Masahiro http://orcid.org/0000-0002-4475-8767
Wang, Bo
Hasegawa, Saki
Fukumoto, Ken
Wasano, Nariaki
Kakitani, Makoto
Ochiai, Nakaba
Kawai, Yohei
Ueda, Tatsuki
Ishikawa, Akihiro
Kurimoto, Yuko
Fukui, Asami
Kamibayashi, Sanae
Imai, Eri
Kunisato, Atsushi
Nozawa, Hajime
Kaneko, Shin http://orcid.org/0000-0003-2291-4586
Funding for this research was provided by:
Kirin Holdings, Co. Ltd.
Article History
Received: 25 May 2022
Accepted: 7 May 2024
First Online: 4 June 2024
Competing interests
: S-i.T., S.C., K.F., A.K., Y.Kawai, and Sh.K. declare a patent titled Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells’ (WO2020116606) related to this work. S-i.T., S.C., S.H., K.F., N.W., N.O., Y.Kurimoto., A.F., A.K., M.K., and H.N. are employed by Kirin Holdings, Co., Ltd. Sh.K. is a founder, shareholder, and board member at Shinobi Therapeutics, Inc., and received research fundings from Kirin Holdings, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Shinobi Therapeutics, Inc., Astellas Co., Ltd., Terumo Co., Ltd., and Tosoh Co., Ltd. The remaining authors declare no competing interests.